

**O1194 Inosine-5'-triphosphatase activity is associated with TDF-associated nephrotoxicity in HIV**

Chantal Peltenburg\*<sup>1</sup>, Ingeborg Wijting<sup>1</sup>, Casper Rokx<sup>1</sup>, Jaap A. Bakker<sup>2</sup>, Bart Rijnders<sup>1</sup>, Jörgen Bierau<sup>3</sup>, Annelies Verbon<sup>1</sup>

<sup>1</sup> Erasmus MC, Rotterdam, Netherlands, <sup>2</sup> Leiden University Medical Center (LUMC), Leiden, Netherlands, <sup>3</sup> Maastricht University Medical Center, Maastricht, Netherlands

**Background:** Nucleotide reverse transcriptase inhibitors play a pivotal role in HIV-treatment. The enzyme Inosine 5'-triphosphatase (ITPase) is involved in the nucleotide metabolism and has been associated with adverse drug events. We studied the association between ITPase-activity and tenofovir disoproxil fumarate (TDF)-associated nephrotoxicity.

**Materials/methods:** Single center 1:2 case control cohort study, including suppressed HIV-infected patients with (cases) and without (controls) TDF-associated nephrotoxicity. 26 cases (eGFR-decline >25% and/or  $\geq 2$  proximal tubular dysfunction (PTD)-markers during TDF use) were matched to 55 controls. ITPase-activity and *ITPA* genotype were measured in all patients. The primary endpoint was the proportion of patients with normal ITPase-activity ( $\geq 4$  mmol IMP/mml Hb/hour) in cases versus controls. The eGFR-improvement 48 weeks after TDF-cessation was measured in cases. McNemar's test, conditional logistic regression, and paired T-tests were used.

**Results:** The eGFR in cases and controls at TDF-discontinuation was 78 and 85 ml/min. 19/26 cases (73.1%) versus 28/55 controls (50.9%) had normal ITPase activity,  $p=0.001$  (OR 2.55, 95% CI 0.89-7.31,  $p=0.08$ ). 23/26 cases (88.5%) versus 40/55 controls (72.7%) had wt/wt *ITPA* genotype,  $p=0.26$  (OR 2.59, 95% CI 0.70-9.54,  $p=0.15$ ). After TDF-cessation, the eGFR increased in cases with normal ITPase activity (-5.5 to +4.4 ml/min/year,  $p=0.008$ ), but remained stable in cases with reduced activity (-4.3 to -4.0,  $p=0.97$ ). In cases with wt/wt *ITPA* genotype, eGFR increased from -5.0 to +3.0 ml/min/year,  $p=0.021$ . 13/16 cases with PTD had normal ITPase activity. Of cases with available data, 50% with normal activity had PTD-recovery after TDF-cessation.

**Conclusions:** Normal ITPase-activity is associated with nephrotoxicity during TDF use and recovery after TDF-cessation. ITPase-activity might function as a screening-tool for probable occurrence and reversibility of TDF-toxicity.

